EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Alternative treatment for recurrent keloids: initial clinical experience with Rhenium-188 using a specialized device

Kgomotso M G Mokoala, Linda Nonjola, Thabiso Moeng, Cecilia Corbett, Martin Magwaza, Gerhard Dahlhoff, Shannon Brown, Nicholas Vetter, Mariza Vorster, Mike Machaba Sathekge iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07184-4 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Kgomotso M G Mokoala und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa. Hauptthemen laut MEDLINE: Rhenium, Keloid, Radioisotopes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Pretoria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Keloids have proved challenging to manage with various therapies providing variable success rates and recurrences. Alternative therapies or a multimodal approach is often necessary to ensure complete eradication and prevent recurrence. The use of radioactive creams or patches embedded with Holmium-166, Phosphorus-32 for superficial skin lesions has been documented to be safe and effective. The use of Rhenium-188 has proved effective in non-melanoma skin cancers. We report on the initial experience with Rhenium-188 SCT in the treatment of recurrent keloid lesions.

Methods

Patients with recurrent keloid lesions were recruited for therapy with Rhenium-188. These patients had failed most forms of therapy including surgery, intralesional steroids and radiation therapy. Treatment with 188 Re via a specialized unit (Rhenium SCT -Oncobeta) was applied onto the keloid lesion. A personalized treatment time was calculated for every patient. Topical 188 Rhenium delivered as a jelly like matrix containing an insoluble dirhenium-heptasulfide was applied to every target lesion in a single session. The goal is to deliver 30 Gy to the deepest part of the lesion per session (3 mm). Patients were followed up at 2 weeks, 1, 3, 6 and 12 months for side effects as well as clinical and cosmetic outcomes.

Results

A total of 58 lesions were treated. Majority of the lesions were in the head and neck region. The smallest area for treatment was 0.25cm 2 and the largest area treated was 46.25cm 2 . With the exception of four patients (2 sessions to the same lesion), all the other patients received a single session of therapy. The mean activity administered was 256,7MBq (range: 35MBq– 663,50MBq). The treatment time averaged 350.89 min (range: 85–1304 min). There was complete response in 72% of the lesions. Hypopigmentation was the commonest expected long term side effect. After a median follow-up period of 37 months (range: 7–53), there was a 7% recurrence rate.

Conclusion

Treatment with 188 Re is a great alternative in patients with keloids that have had minimal success with other therapies. The use of the specialized applicator system provides great flexibility, reduced morbidity and great results that are comparable to other therapies. Clinical trial number Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RheniumKeloidRadioisotopesHumansMaleFemaleAdultMiddle AgedRecurrenceTreatment OutcomeAged

Stichwörter der Autor:innen

188ReKeloidsRhenium SCTSingle session therapy

Substanzen

RheniumRadioisotopesRhenium-188

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa.
  • Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, South Africa.
  • Oncobeta Africa and Tautomer Biosciences, Pretoria, South Africa.
  • Oncobeta GmbH, Munchen, Munich, Germany.
  • Inkosi Albert Luthuli Central Hospital, University of Kwazulu Natal, Durban, South Africa.
  • Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa. mike.sathekge@up.ac.za.

ORCID-Profile: Mike Machaba Sathekge

Förderung

  • University of Pretoria

Zitieren

APA

Mokoala, K. M. G., Nonjola, L., Moeng, T., Corbett, C., Magwaza, M., Dahlhoff, G., Brown, S., Vetter, N., Vorster, M., & Sathekge, M. M. (2025). Alternative treatment for recurrent keloids: initial clinical experience with Rhenium-188 using a specialized device. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07184-4

Vancouver

Mokoala KMG, Nonjola L, Moeng T, Corbett C, Magwaza M, Dahlhoff G, et al. Alternative treatment for recurrent keloids: initial clinical experience with Rhenium-188 using a specialized device. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07184-4

BibTeX
@article{Mokoala2025,
  author = {Mokoala, Kgomotso M G and Nonjola, Linda and Moeng, Thabiso and Corbett, Cecilia and Magwaza, Martin and Dahlhoff, Gerhard and Brown, Shannon and Vetter, Nicholas and Vorster, Mariza and Sathekge, Mike Machaba},
  title = {Alternative treatment for recurrent keloids: initial clinical experience with Rhenium-188 using a specialized device},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07184-4}
}
Kostenlos starten →